1. The board and management (which are responsible for this mess) go over to Petros while Dr. Alkon stays with the Neurotrope spin-off. Hopefully this means the spin-off gets a new board and management while Dr. Alkon can keep working on synthetic Bryo-1.
2. All Neurotrope warrants and options are converted to Petros warrants and options, which makes the balance sheet for the spin-off much much cleaner.
3. If you're like me and don't feel like investing in a penis pill company, you can just sell the Petros shares (whose worth will include the cash the new company gets) and use it for something else.
The way I see this, it's a neat way to dump the trash at the new company while the spin-off gets a fresh start. The spin-off will probably have to raise cash again next year, but in that case you can just sell everything now and buy in before or after the next results are out.
Market Data 
Markets 
AI
